Table 1.

Clinical characteristics and laboratory results

VariableControl (n=87)Stage 5 CKD Patients (n=118)PNon-PTX Group (n=81)PTX Group (n=37)
Nonfollow-Up (n=16)Successful PTX Follow-Up (n=17)Unsuccessful PTX Follow-Up (n=4)Total (n=37)
Demographics
 Age (yr)47.1±12.450.3±13.20.0852.6±13.441.9±9.348.8±12.144.5±8.945.2±11.1a
 Men/women39/4861/570.4040/419/78/94/021/16
 Body mass index (kg/m2)23.7±2.921.9±3.2<0.00122.0±3.220.3±3.522.4±2.622.2±3.621.6±3.2
 Systolic BP (mmHg)121.1±15.3141.8±27.0<0.001144.6±25.9135.3±31.3134.2±22.9147.8±42.7135.6±28.6
 Diastolic BP (mmHg)78.7±11.184.0±15.00.00483.8±13.186.6±22.983.2±16.788.8±15.584.5±18.7
Dialysis mode, n (%)
 Predialysis0 (0.0)5 (4.2)<0.0015 (6.2)0 (0.0)0 (0.0)0 (0.0)0 (0.0)
 Hemodialysis0 (0.0)95 (80.5)<0.00159 (72.8)16 (100.0)16 (94.1)4 (100.0)36 (97.3)a
 Peritoneal dialysis0 (0.0)18 (15.3)<0.00117 (21.0)0 (0.0)1 (5.9)0 (0.0)1 (2.7)b
Dialysis vintage (mo)0 (0.0–0.0)30.0 (6.0–86.3)<0.00110.0 (4.0–36.0)97.0 (60.0–128.3)87.0 (63.0–127.0)a91.0 (48.5–179.3)94.0 (63.0–126.5)a
Comorbidities, n (%)
 Diabetic mellitus0 (0.0)26 (22.0)<0.00124 (29.6)0 (0.0)1 (5.9)1 (25.0)2 (5.4)a
 Hypertension11 (12.6)88 (74.6)<0.00164 (79.0)10 (62.5)13 (76.5)1 (25.0)24 (64.9)
Cause of ESRD, n (%)
 GN0 (0.0)72 (61.0)<0.00145 (55.6)11 (68.8)13 (76.5)3 (75.0)27 (73.0)
 Diabetic nephropathy0 (0.0)12 (10.2)<0.00111 (13.6)0 (0.0)0 (0.0)1 (25.0)1 (2.7)
 Hypertensive nephropathy0 (0.0)2 (1.7)<0.0011 (1.2)0 (0.0)1 (5.9)0 (0.0)1 (2.7)
 Polycystic kidney disease0 (0.0)6 (5.1)<0.0014 (4.9)1 (6.3)1 (5.9)0 (0.0)2 (5.4)
 Other0 (0.0)26 (22.0)<0.00120 (24.7)4 (25.0)2 (11.8)0 (0.0)6 (16.2)
Medication history, n (%)
 Calcium channel blocker2 (2.3)76 (64.4)<0.00156 (69.1)9 (56.3)10 (58.8)1 (25.0)20 (54.1)
 ACEI/ARB3 (3.4)39 (33.1)<0.00128 (34.6)5 (31.3)5 (29.4)1 (25.0)11 (29.7)
 β-Receptor blocker0 (0.0)35 (29.7)<0.00124 (29.6)3 (18.8)8 (47.1)0 (0.0)11 (29.7)
Laboratory values
 Hemoglobin (g/L)143.2±16.895.6±22.9<0.00192.6±22.0100.3±30.4102.5±17.1102.3±15.9102.3±23.7b
 Hematocrit (%)42.7±4.429.2±7.0<0.00128.0±6.631.8±9.831.5±5.0b32.0±5.531.8±7.4a
 Glucose (mmol/L)5.4±0.85.3±2.60.575.6±2.74.0±0.54.9±3.44.8±1.44.5±2.3b
 Creatinine (μmol/L)68.7±14.2874.4±318.5<0.001861.1±343.5864.7±255.3905.6±273.9926.1±143.2903.5±257.4
 Urea (mmol/L)5.7±1.223.5±8.6<0.00124.4±9.120.2±7.123.0±7.818.9±2.421.7±7.2
 HDL cholesterol (mmol/L)1.4±0.31.1±0.3<0.0011.1±0.31.2±0.41.1±0.31.1±0.41.1±0.3
 LDL cholesterol (mmol/L)2.8±0.62.6±0.90.202.8±1.02.4±0.72.3±0.5a2.3±0.62.4±0.6a
 Total cholesterol (mmol/L)5.0±0.84.4±1.3<0.0014.5±1.44.4±1.14.0±0.83.8±1.04.1±1.0
 Triglyceride (mmol/L)1.4±1.51.6±1.00.391.7±1.11.3±0.71.3±0.61.2±0.51.3±0.7b
 Albumin (g/L)48.2±2.637.2±5.9<0.00136.4±6.638.3±3.838.8±4.839.8±3.738.7±4.2b
Bone metabolism panel
 Calcium (mg/dl)9.4±0.49.3±1.30.388.8±1.210.2±1.010.5±0.6a10.4±1.010.3±0.8a
 Phosphorus (mg/dl)3.7±0.56.1±1.7<0.0015.8±1.66.5±1.96.9±1.8b6.2±1.66.7±1.9a
 ALP (μ/L)73.2 (61.0–86.4)105.7 (78.9–220.2)<0.00189.0 (75.6–114.6)254.9 (145.4–957.6)527.3 (228.3–1006.8)a285.8 (152.6–570.0)351.5 (161.8–937.5)a
 iPTH (pg/ml)37.0 (29.0–51.4)442.3 (191.3–1257.7)<0.001228.0 (156.5–530.6)1701.8 (1062.3–2384.0)1717.8 (1350.8–3209.7)a1639.9 (1491.3–2908.1)1717.5 (1294.9–2521.6)a
 ln iPTH3.6±0.46.1±1.3<0.0015.5±1.07.4±0.57.5±0.4a7.5±0.47.5±0.4a
  • Data are mean ± SD, numbers and percentages, or median (25th to 75th percentile) as appropriate. Test of significance was by independent samples t or Wilcoxon rank sum test for continuous variables and chi-squared or Fisher exact test for categorical variables. PTX, parathyroidectomy; ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blocker; ALP, alkaline phosphatase; iPTH, intact parathyroid hormone.

  • a P<0.01 versus non-PTX group.

  • b P<0.05 versus non-PTX group.